



G Medical Innovations Holdings Ltd  
ARBN 617 204 743

## ASX Announcement

6 April 2020

### PERMIT LICENCE FOR PRIZMA RECEIVED FROM TAIWAN FDA

- **Prizma now licensed for use in Taiwan by Taiwan Food and Drug Administration**
- **Prizma device can detect and monitor symptoms associated with infection and acute and chronic illness**
- **Significant achievement allows GMV to progress Taiwan market entry**
- **Commercial negotiations are ongoing G Medical's existing in country partners**

Mobile and e-Health company **G Medical Innovations Holdings Limited (ASX:GMV)** ("**G Medical**" "**the Company**"), is pleased to advise that through its partners First Channel Ltd ("**FCL**"), it has received a permit license ("**Permit License**") for G Medical's Prizma device in Taiwan.

The Permit License was granted by the Taiwan Food and Drug Administration ("**FDA**") following the provision of ancillary product information (including packaging and labelling) from FCL (refer ASX announcement: 20 January 2020).

The Prizma is used by everyday consumers to monitor vital signs including temperature, heart rate, stress levels, SPO<sub>2</sub> (blood oxygen saturation) and electrocardiography (ECG), all of which are physiological biometrics that can be measured to detect symptoms associated with infection and chronic illness.

Given the current world focus on telehealth technologies and the considerable increase in demand the Company is witnessing, G Medical is confident that the Prizma will be well received by consumers and healthcare professionals. The Company will further benefit as countries continue to push towards telehealth solutions and connected care in particular consideration of out-of-clinic and isolated vital sign monitoring requirements.

G Medical and FCL continue to delineate commercial strategies for the Taiwanese market, with the commencement of distribution of the Company's medical products via FCL remaining subject to FCL finalising and entering into additional definitive agreements with FCL's third party partners (refer ASX announcement: 10 November 2017).

G Medical is currently exploring additional partnerships within Taiwan and looks forward to updating shareholders as developments progress.

**CEO and Executive Director Dr Yacov Geva said:** "This development is another major step forward for G Medical and it provides G Medical with another competitive advantage in Taiwan. The Prizma device can be used to monitor symptoms associated with infection and chronic and acute illness, so we are confident that the device will resonate with consumers.

“Given the importance to medical solutions such as the Prizma in the current climate, we will progress discussions with FCL to delineate a commercial strategy as quickly as possible. We look forward to updating shareholders as developments progress.”

**Ends**

*This announcement was authorised for release by Yacov Geva, Managing Director.*

**Released through:** Henry Jordan, Six Degrees Investor Relations: +61 (0) 431 271 538

**About G Medical Innovations**

G Medical (**ASX: GMV**) was founded in August 2014, aiming to be at the forefront of the digital health revolution, developing the next generation of mobile health (mHealth) technologies. The Company leverages the experience and expertise of its Board to deliver best-in-class solutions to address this global opportunity.

The Company specialises in innovative next generation mobile and e-health solutions using its suite of proprietary devices and software solutions, as well as patient service operations, with a view to driving multiple and recurring revenue streams, across numerous verticals and territories.

For more information on G Medical, please visit [www.gmedinnovations.com](http://www.gmedinnovations.com)

**About G Medical products:**

G Medical offers a suite of consumer and professional clinical-grade products (with regulatory approval) that are positioned to streamline healthcare services, improve remote access to medical data, reduce costs, improve quality of care, and make healthcare more personalized and precise. Currently the Company is focusing on two main verticals.

The ‘Prizma’ Medical Smartphone Case is one of two key products developed by G Medical and is aimed at everyday consumers focused on their medical health and wellbeing. The ‘Prizma’ allows consumers to turn their smartphone into a mobile medical monitor to measure a wide range of vital signs, with the added advantage that users are able to store their medical data in the cloud and share it with third parties such as healthcare professionals and family members.

G Medical also offers a professional real-time patient continuous monitoring solution, G Medical’s Vital Signs Monitoring System (VSMS) and G Medical Patch (GMP). This modular solution measures a wide range of vital signs that are automatically presented in a call centre (IDTF) or a hospital setting. The GMP assists in diagnosing patient complaints and conditions remotely, from pre-hospitalisation, hospitalisation and through to post discharge home-based settings.